The Use of DPP-4 Inhibitors in Short Bowel Syndrome (DPP-4)
The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome
Sponsor: Stanley Dudrick's Memorial Hospital
Terminated
too many side-effects
Other Short Bowel Syndrome trials with similar outcome
This PHASE4 trial investigates Short Bowel Syndrome and is currently terminated or withdrawn. Stanley Dudrick's Memorial Hospital leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Jan 2019 — May 2020 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stanley Dudrick's Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .